Feb. 16, 2021 12:00 UTC
-ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-
-ADG20 binds to a highly conserved region of the spike protein not targeted by other antibodies, enabling potent neutralization to all known SARS-CoV-2 variants and several pre-emergent coronavirus threats-
WALTHAM, Mass.--(BUSINESS WIRE)-- Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the initiation of a Phase 1 clinical trial evaluating its lead monoclonal antibody product candidate, ADG20. The Phase 1 trial will be conducted in the United States and will evaluate the safety, tolerability and pharmacokinetics of ADG20, including serum SARS-CoV-2 neutralizing antibody levels, in healthy participants. Once adequate safety data are evaluated, Adagio plans to advance ADG20 into global pivotal trials for the treatment and prevention of COVID-19, including in countries with high rates of resistant variants.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005243/en/
Tillman Gerngross, Co-Founder and CEO, Adagio Therapeutics, Inc. (Photo: Business Wire)
We are in the unique position of having a monoclonal antibody that binds to and protects against common circulating SARS-CoV-2 variants as well as SARS-related viruses with pandemic potential. This broadly neutralizing activity was intentionally designed into ADG20, as we anticipated the continued emergence of resistance mutations, and we took deliberate steps to engineer ADG20 to maximize its potential to avoid viral escape. This design feature also enables ADG20 to target and neutralize coronaviruses that may emerge in the future, said Tillman Gerngross, Chief Executive Officer of Adagio. Were very proud of the impressive work the team at Adagio has done, rapidly moving from lead identification and manufacturing into clinical trials within eight months.
This Phase 1 study is the first step in the clinical development of ADG20, our broadly-neutralizing antibody for coronavirus threats, and we expect it to provide key information regarding safety, pharmacokinetics and serum SARS-CoV-2 neutralizing antibody levels, said Lynn Connolly, Chief Medical Officer of Adagio. We plan to evaluate intramuscular administration of ADG20, which could be a critical differentiator for patients and providers, allowing for administration in the community setting for both prevention and treatment of COVID-19. We will be evaluating ADG20 across multiple clinical settings on a global basis from pre- and post-exposure prophylaxis to treatment. We are currently focused on outpatient populations, including an emphasis on addressing unmet needs in vulnerable groups such as the immune compromised and children.
In this Phase 1, randomized, double-blind, single ascending-dose study, healthy adult participants will either receive an intramuscular or intravenous dose of ADG20 or placebo. The primary endpoint of the study is safety and tolerability, while secondary endpoints include evaluations of pharmacokinetics and immunogenicity. The study will also explore the serum neutralizing activity of ADG20 ex vivo against SARS-CoV-2.
In closing, Gerngross notes, We believe ADG20 is poised to address the endemic nature of SARS-CoV-2 as well as the pandemic potential of future coronaviruses. We are excited to initiate clinical trials and potentially commercialize a differentiated antibody whose combined attributes address key limitations of other antibody programs and have the potential to address the significant unmet need that remains in the treatment and prevention of COVID-19.
About Adagio Therapeutics
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses. Our candidates are optimized using Adimabs industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability. Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes. Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs. We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021. Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information: http://www.adagiotx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005243/en/
See the article here:
- About Us [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Contact Us [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Prometheism Home [Last Updated On: November 9th, 2009] [Originally Added On: November 9th, 2009]
- Euvolution Home [Last Updated On: November 9th, 2009] [Originally Added On: November 9th, 2009]
- Puzzles and Chemistry | LP Amnesia: The Dark Descent | #3 - Video [Last Updated On: August 18th, 2024] [Originally Added On: May 11th, 2014]
- Technocalpyse Part 1, 2, 3 [Last Updated On: August 18th, 2024] [Originally Added On: January 24th, 2016]
- Regenerative Medicine Conferences | Europe | CPD Events ... [Last Updated On: August 18th, 2024] [Originally Added On: July 8th, 2016]
- IRM at UPenn - Institute For Regenerative Medicine - Phila [Last Updated On: August 18th, 2024] [Originally Added On: July 8th, 2016]
- Organogenesis.com - Science - Regenerative Medicine [Last Updated On: August 18th, 2024] [Originally Added On: July 8th, 2016]
- Regenerative Medicine - WOMEN IN MEDICINE LTD [Last Updated On: August 18th, 2024] [Originally Added On: July 8th, 2016]
- Regenerative medicine consultation service - Mayo Clinic ... [Last Updated On: August 18th, 2024] [Originally Added On: September 8th, 2016]
- Anatomy of a Lie: How Iran Covered Up the Downing of an Airliner - The New York Times [Last Updated On: August 17th, 2024] [Originally Added On: January 28th, 2020]
- Tips to Take Care of a Rescue Animal [Last Updated On: August 18th, 2024] [Originally Added On: June 1st, 2020]
- Meditation initiative benefits healthcare workers - CapeGazette.com [Last Updated On: August 17th, 2024] [Originally Added On: June 8th, 2020]
- Ethereum Posts 450% Gain in 2020, Beats Bitcoin - Finance Magnates [Last Updated On: January 5th, 2021] [Originally Added On: January 5th, 2021]
- Nanotechnology in Medical Market Demand Analysis To 2026 Lead By-Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune KSU | The... [Last Updated On: August 18th, 2024] [Originally Added On: February 12th, 2021]
- Crypto market report: Bitcoin, Ethereum, Litecoin & Co .: How the crypto prices develop on Saturday | message - The Times Hub [Last Updated On: February 17th, 2021] [Originally Added On: February 17th, 2021]
- Mental Stimulation For The Elderly: Why Is It So Important? [Last Updated On: August 18th, 2024] [Originally Added On: July 1st, 2021]
- How To Live With Less Sugar In Your Diet - Longevity LIVE - Longevity LIVE [Last Updated On: August 18th, 2024] [Originally Added On: August 3rd, 2021]
- 7 ways to keep mosquitoes away from your baby [Last Updated On: August 18th, 2024] [Originally Added On: August 3rd, 2021]
- Common Myths About Hair Transplants [Last Updated On: August 18th, 2024] [Originally Added On: August 26th, 2021]
- CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop "off-the-shelf" CAR-iMAC cell therapy | DNA... [Last Updated On: August 18th, 2024] [Originally Added On: September 7th, 2022]
- Let’s go with 8 Health Benefits of Doing Yoga Every Day. [Last Updated On: August 18th, 2024] [Originally Added On: June 9th, 2023]
- Digital Growth Strategies: Web and Mobile App Development in Dubai [Last Updated On: August 18th, 2024] [Originally Added On: September 11th, 2023]
- Unlock Your Everyday Radiance: Steps to Look and Feel Your Best [Last Updated On: August 18th, 2024] [Originally Added On: December 13th, 2023]
- Supporting Loved Ones: Meaningful Ways to Assist with Chronic Health Care [Last Updated On: August 18th, 2024] [Originally Added On: January 28th, 2024]
- Ease Inflammation and Embrace Vitality With This Healthy Living Guide [Last Updated On: August 18th, 2024] [Originally Added On: February 6th, 2024]
- Optimizing Wellness: Essential Strategies for Healthy Business Travel [Last Updated On: August 18th, 2024] [Originally Added On: August 1st, 2024]